Drugs / ASAPIPRANT
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04705597 | Mar 2021 → Apr 2022 | COVID-19 | BioAge Labs, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01651871 | Jul → Nov 2012 | seasonal allergic rhinitis | Shionogi | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASAPIPRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545043 ↗ |
| Known as | BGE-175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04705597 ↗ |
| Known as | S-555739 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01651871 ↗ |
| Action | Inhibit | “Prostanoid DP receptor antagonist” CHEMBL3545043 ↗ |
| Modality | Small molecule | — CHEMBL3545043 ↗ |
| Route | Oral | “BGE-175 administered PO or NG” NCT04705597 ↗ |
| Target | PTGDR | “Prostanoid DP receptor antagonist” CHEMBL3545043 ↗ |